CIS Pharma summer event in Alsace
Strasbourg, France, Thursday, July 20, 2017 - The CIS Pharma Summer Event takes us to Alsace, France. Our first stop is well known in France and abroad for its foie [...]
Besponsa, a new antibody-drug conjugate, ADC, approved in the EU
London, GB, Thursday, June 29, 2017 - The ADC Besponsa - inotuzumab ozogamicin, Pfizer Inc. - is a cancer medicine used to treat a type of blood cancer which affects [...]
CIS Pharma presenting ADC drug carrier technology at Swiss Biotech Day 2017
Basel, Switzerland, Thursday, May 4, 2017 - CIS Pharma presents its ADC drug carrier technology at Swiss Biotech Day 2017, scheduled for 14:10 during the Emerging Companies Streams. CIS Pharma [...]
CIS Pharma starts R&D project by SNI for 3D printed biocompatible membranes for tissue regeneration
Bubendorf, Switzerland, Wednesday, April 26, 2017 - The Swiss Nanoscience Institute has granted CIS Pharma funding for an innovative project in the field of implantology. The Project is a collaboration [...]
CIS Pharma team attends Pharmapack 2017 in Paris
Paris, France, Wednesday to Thursday, February 1 to 2, 2017 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the two-day conference in Paris. The [...]
CIS Pharma appoints Dr. Christophe Thommen as new head of research and laboratory operations
Bubendorf, Switzerland, Thursday, December 1, 2016 - CIS Pharma welcomes Dr. Christophe Thommen, who will lead the research team as the new head of research and laboratory operations. Christophe is [...]
CIS Pharma’s solubilization technology comprising cyclosporine A has entered proof of concept phase
Bubendorf, Switzerland, Friday, October 21, 2016 - CIS Pharma’s novel solubilization strategy for hydrophobic drugs has successfully reached the proof of concept phase. The Cellophil® Smart Polymer technology platform creates [...]
CIS Pharma team attends CPhI Worlwide 2016 in Barcelona
Barcelona, Spain, Tuesday to Thursday, October 4 to 6, 2016 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the three-day conference in Barcelona. The [...]
CIS Pharma has successfully concluded the development of novel contact lens coating technology
Bubendorf, Switzerland, Monday, September 5, 2016 - CIS Pharma has concluded the development of a novel contact lens coating technology based on the Cellophil® Smart Polymer platform. The technology has [...]
CIS Pharma to launch new web presence
Bubendorf, Switzerland, Monday, August 1, 2016 - CIS Pharma’s new company website is online. The site was established in collaboration with SKYWEB, a fast-growing start-up incorporated in close proximity to [...]